(2nd item) New Data Updating Overall Survival Rate in Olaparib Study -- SGO conference

New Data Updating Overall Survival Rate in Olaparib Study -- AUSTIN, Texas, March 27, 2012 /PRNewswire-USNewswire/ --SGO conference

Medical News:Data Confirm PARP Inhibitor (Olaparib) Slows Ovarian Ca - in Meeting Coverage, SGO from MedPage Today

Medical News:Data Confirm PARP Inhibitor Slows Ovarian Ca - in Meeting Coverage, SGO from MedPage Today

Action Points

Note that this randomized, placebo controlled study demonstrates that olaparib, an oral poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor, significantly improved progression-free survival but not overall survival, in patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer.

index of abstracts: Gynecologic Oncology | Vol 125, Supplement 1, Pgs S1-S188, (March, 2012) | ScienceDirect.com

Gynecologic Oncology | Vol 125, Supplement 1, Pgs S1-S188, (March, 2012) | ScienceDirect.com


ABSTRACTS PRESENTED FOR THE 43RD ANNUAL MEETING OF THE SOCIETY OF GYNECOLOGIC ONCOLOGY AUSTIN, TX USA, 

abstracts: 42nd annual SGO meeting - Gynecologic Oncology | Vol 125, Supplement 1, Pgs S1-S188, (March, 2012)

2012 Annual Meeting on Womens Cancer March 24-27 Austin, Texas | The Society of Gynecologic Oncology (new conference website)

Annual Meeting on Womens Cancer | The Society of Gynecologic Oncology

Registration Links

Registration Registration Category/Fees Registration Cancellation Policy Schedule of Events (pdf)